Treace to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) will announce its financial results for Q4 and the full year of 2021 on March 3, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET, where management will discuss these results. Interested investors can join the call by dialing (888) 708-0264 domestically or (720) 405-2122 internationally, using Conference ID: 6356356. Treace is known for the Lapiplasty® 3D Bunion Correction™ System and recently introduced the Adductoplasty™ Midfoot Correction System to enhance treatment options for bunion deformities.

Positive

• Scheduled financial results announcement for Q4 and full-year 2021 on March 3, 2022.
• Introduction of Adductoplasty™ Midfoot Correction System to expand treatment offerings.

Negative

• None.

PONTE VEDRA, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Thursday, March 3, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (888) 708-0264 for domestic callers or (720) 405-2122 for international callers, followed by Conference ID: 6356356. A live and archived webcast of the event will be available on the Company’s investors relations website at https://investors.treace.com/.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ System - a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot which could provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net

 

FAQ

When will Treace Medical Concepts release its Q4 2021 financial results?

Treace Medical Concepts will release its Q4 2021 financial results on March 3, 2022.

What is the scheduled time for Treace's financial results conference call?

The financial results conference call is scheduled for 4:30 p.m. ET on March 3, 2022.

How can investors join Treace's conference call for financial results?

Investors can join the conference call by dialing (888) 708-0264 for domestic calls or (720) 405-2122 for international calls, using Conference ID: 6356356.

What new product has Treace recently introduced?

Treace has recently introduced the Adductoplasty™ Midfoot Correction System.